




The relative strengths and weaknesses of Revance Therapeutics Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Revance Therapeutics Inc compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 147% points. The greatest weakness of Revance Therapeutics Inc is the variable Other Revenues, reducing the Economic Capital Ratio by 13% points.

The company's Economic Capital Ratio, given in the ranking table, is 383%, being 120% points above the market average of 263%.

Input Variable	Value in 1000 USD
Assets, Current	253,963
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	12,037
Liabilities, Non-Current	0
Other Assets	2,151
Other Compr. Net Income	-40
Other Expenses	1,190
Other Liabilities	10,533
Other Net Income	31
Other Revenues	300
Property and Equipment	19,708
Research and Development	47,529
Selling, General and Administrative Expense	25,088

Output Variable	Value in 1000 USD
Assets	275,822
Liabilities	22,570
Expenses	73,807
Revenues	300
Stockholders Equity	253,252
Net Income	-73,476
Comprehensive Net Income	-73,496
BaseVar	186,285
ECR before Limited Liability	321%
Economic Capital Ratio	383%